News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NeuroDerm Ltd. Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease


6/19/2013 10:34:35 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NESS ZIONA, Israel, June 19, 2013 -- /PRNewswire/ -- NeuroDerm, Ltd. today announced that results from a phase I study in volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, were presented at the 2013 International Congress of Parkinson's Disease and Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for continuous administration through a sub-cutaneous (SC) delivery patch that would maintain constant levodopa plasma concentrations. Read more here: http://www.sacbee.com/2013/06/19/5508091/neuroderm-announces-presentation.html#storylink=cpy

Help employers find you! Check out all the jobs and post your resume.

Read at Sacramento Bee

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES